Advertisement

Pathology & Oncology Research

, Volume 25, Issue 1, pp 241–247 | Cite as

Outcome of Restarted Sunitinib Treatment in Patients with Metastatic Renal Cell Carcinoma: a Retrospective Trial and Combined Case Reports from Literature

  • Krisztián Nagyiványi
  • Barna BudaiEmail author
  • Zsófia Küronya
  • Fruzsina Gyergyay
  • Krisztina Bíró
  • István Bodrogi
  • Lajos Géczi
Article
  • 152 Downloads

Abstract

In practice it is still not clear whether a drug holiday in sunitinib (Su) treatment can be safety, without impairing the overall outcome of patients with metastatic renal cell carcinoma (mRCC). The aim was to retrospectively evaluate the outcome in patients who restarted Su after an interruption of ≥3 months and a combined analysis of case studies from literature. From 556 patients treated between January 2006 and March 2016 a group of 38 patients were selected whose treatment was interrupted for other reasons than disease progression. During interruption Su was restarted in case of RECIST-defined progression. The primary objective was the objective response (OR) and progression free survival (PFS) of baseline and restarted therapy. The secondary objective was the overall survival (OS) calculated from the start of baseline treatment. Multivariate survival analysis was also applied. The major causes of interruption were toxicity (39%) and patient’ choice (24%). Median duration of interruption was 7 (range 3–41) months. The OR of baseline and restarted treatment was 63% and 39%, respectively. After a median follow-up of 76 (95% CI 65–79) months the median PFS of baseline and restarted treatment was 21 (18–27) and 14 (10–18) months, respectively. The median OS was 61 (56–80) months. In multivariate analysis the lack of OR of restated treatment was an independent predictor of shorter PFS of restarted Su. According to our findings and also on combined case studies from literature restarted Su can be effective in selected cases of patients who progressed during treatment holiday.

Keywords

Drug holiday Overall survival Patient’s choice Progression-free survival Toxicity 

Notes

Funding

This research has no funding support.

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Koo DH, Park I, Ahn JH et al (2016) Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma. Cancer Chemother Pharmacol 77:339–347.  https://doi.org/10.1007/s00280-015-2942-1 CrossRefGoogle Scholar
  2. 2.
    Griffioen AW, Mans LA, de Graaf AM et al (2012) Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients. Clin Cancer Res 18:3961–3971.  https://doi.org/10.1158/1078-0432.CCR-12-0002 CrossRefGoogle Scholar
  3. 3.
    Albiges L, Oudard S, Negrier S et al (2012) Complete remission with tyrosine kinase inhibitors in renal cell carcinoma. J Clin Oncol 30:482–487.  https://doi.org/10.1200/JCO.2011.37.2516 CrossRefGoogle Scholar
  4. 4.
    Johannsen M, Staehler M, Ohlmann CH et al (2011) Outcome of treatment discontinuation in patients with metastatic renal cell carcinoma and no evidence of disease following targeted therapy with or without metastasectomy. Ann Oncol 22:657–663.  https://doi.org/10.1093/annonc/mdq437 CrossRefGoogle Scholar
  5. 5.
    Nagyiványi K, Budai B, Bíró K et al (2016) Synergistic survival: a new phenomenon connected to adverse events of first-line sunitinib treatment in advanced renal cell carcinoma. Clin Genitourin Cancer 14:314–322.  https://doi.org/10.1016/j.clgc.2015.11.016 CrossRefGoogle Scholar
  6. 6.
    Ornstein MC, Wood LS, Elson P et al (2017) A phase II study of intermittent sunitinib in previously untreated patients with metastatic renal cell carcinoma. J Clin Oncol 35:1764–1769.  https://doi.org/10.1200/JCO.2016.71.1184
  7. 7.
    Johannsen M, Flörcken A, Bex A et al (2009) Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis. Eur Urol 55:1430–1438.  https://doi.org/10.1016/j.eururo.2008.10.021 CrossRefGoogle Scholar
  8. 8.
    Miura Y, Fujii Y, Shimomura A et al (2014) Temporal cessation of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective study. Ann Oncol 25(Suppl.5):v46.  https://doi.org/10.1093/annonc/mdu435.10
  9. 9.
    Demiselle J, Lheureux S, Clarisse B et al (2011) Metastatic renal cancer: evolution of five complete response cases after the antiangiogenic discontinuation. Bull Cancer 98:626–632.  https://doi.org/10.1684/bdc.2011.1368 Google Scholar
  10. 10.
    Bono P ESMO e-learning: renal cell cancer - clinical case study 1 and 2. http://oncologypro.esmo.org/content/download/22271/368712/file/Renal-Cell-Cancer-Bono.pdf
  11. 11.
    Vaz MA, Pachón V, Grande E et al (2011) Complete response to sunitinib in a patient with relapsed irresectable renal cell carcinoma. Anti-Cancer Drugs 22(8):817–821.  https://doi.org/10.1097/CAD.0b013e3283437ff9 CrossRefGoogle Scholar
  12. 12.
    Zhao B, Wood LS, James K, Rini BI (2015) Is it safe to restart antivascular endothelial growth factor therapy in patients with renal cell carcinoma after cardiac ischemia? Case Rep Oncol Med 2015:817578.  https://doi.org/10.1155/2015/817578 Google Scholar
  13. 13.
    Calvo OF, Vázquez DD, López MR, Aparicio LM (2010) Renal cell carcinoma: complete response. Anti-Cancer Drugs 21(Suppl 1):S17–S18.  https://doi.org/10.1097/01.cad.0000361531.59299.5a CrossRefGoogle Scholar
  14. 14.
    Paule B, Brion N (2010) Efficacy of sunitinib in patients with renal cell carcinoma with bone metastases. Anticancer Res 30:5165–5168Google Scholar
  15. 15.
    Shablak A, O'Dwyer J, Hawkins R, Board R (2011) Management of a new isolated metastasis during sunitinib treatment in renal cell carcinoma patients: a lesson from two cases. Urol Int 86:245–248.  https://doi.org/10.1159/000321908 CrossRefGoogle Scholar
  16. 16.
    Gomez-Abuin G, Karam AA, Mezzadri NA, Bas CA (2009) Acalculous cholecystitis in a patient with metastatic renal cell carcinoma treated with sunitinib. Clin Genitourin Cancer 7:62–63.  https://doi.org/10.3816/CGC.2009.n.011 CrossRefGoogle Scholar
  17. 17.
    van der Veldt AA, van den Eertwegh AJ, Boven E (2007) Adverse effects of the tyrosine-kinase inhibitor sunitinib, a new drug for the treatment of advanced renal-cell cancer. Ned Tijdschr Geneeskd 151:1142–1147Google Scholar
  18. 18.
    Szmit S, Zagrodzka M, Kurzyna M et al (2009) Sunitinib malate, a receptor tyrosine kinase inhibitor, is effective in the treatment of restrictive heart failure due to heart metastases from renal cell carcinoma. Cardiology 114:67–71.  https://doi.org/10.1159/000213049 CrossRefGoogle Scholar
  19. 19.
    Kim H, Shoji S, Usui Y et al (2013) A case of complete response of multiple lung metastases of renal cell carcinoma with the flexible administration of sunitinib. Hinyokika Kiyo 59:7–10Google Scholar
  20. 20.
    Fukui S, Toyoshima Y, Inoue T et al (2016) Reversible posterior leukoencephalopathy syndrome developing after restart of sunitinib therapy for metastatic renal cell carcinoma. Case Rep Med 2016:6852951.  https://doi.org/10.1155/2016/6852951 CrossRefGoogle Scholar
  21. 21.
    Schmidinger M, Larkin J, Ravaud A (2012) Experience with sunitinib in the treatment of metastatic renal cell carcinoma. Ther Adv Urol 4:253–265.  https://doi.org/10.1177/1756287212454933 CrossRefGoogle Scholar
  22. 22.
    Schmidinger M, Bojic A, Vogl UM et al (2009) Management of cardiac adverse events occurring with sunitinib treatment. Anticancer Res 29:1627–1629Google Scholar
  23. 23.
    Molina AM, Jia X, Feldman DR et al (2013) Long-term response to sunitinib therapy for metastatic renal cell carcinoma. Clin Genitourin Cancer 11:297–302.  https://doi.org/10.1016/j.clgc.2013.04.001 CrossRefGoogle Scholar
  24. 24.
    Iacovelli R, Massari F, Albiges L et al (2015) Evidence and clinical relevance of tumor flare in patients who discontinue tyrosine kinase inhibitors for treatment of metastatic renal cell carcinoma. Eur Urol 68:154–160.  https://doi.org/10.1016/j.eururo.2014.10.034 CrossRefGoogle Scholar
  25. 25.
    Hammers HJ, Verheul HM, Salumbides B et al (2010) Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study. Mol Cancer Ther 9:1525–1535.  https://doi.org/10.1158/1535-7163.MCT-09-1106 CrossRefGoogle Scholar
  26. 26.
    Collinson FJ, Gregory WM, McCabe C et al (2012) The STAR trial protocol: a randomised multi-stage phase II/III study of Sunitinib comparing temporary cessation with allowing continuation, at the time of maximal radiological response, in the first-line treatment of locally advanced/metastatic renal cancer. BMC Cancer 12:598.  https://doi.org/10.1186/1471-2407-12-598 CrossRefGoogle Scholar
  27. 27.
    Greef B, Eisen T (2016) Medical treatment of renal cancer: new horizons. Br J Cancer 115:505–516.  https://doi.org/10.1038/bjc.2016.230 CrossRefGoogle Scholar

Copyright information

© Arányi Lajos Foundation 2017

Authors and Affiliations

  • Krisztián Nagyiványi
    • 1
  • Barna Budai
    • 1
    Email author
  • Zsófia Küronya
    • 1
  • Fruzsina Gyergyay
    • 1
  • Krisztina Bíró
    • 1
  • István Bodrogi
    • 1
  • Lajos Géczi
    • 1
  1. 1.National Institute of OncologyBudapestHungary

Personalised recommendations